The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! About 996,132 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 28.80% since March 9, 2016 and is downtrending. It has underperformed by 36.21% the S&P500.
The move comes after 8 months negative chart setup for the $2.78B company. It was reported on Oct, 12 by Barchart.com. We have $25.62 PT which if reached, will make NASDAQ:JUNO worth $166.80M less.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on November, 8. They expect $-0.64 EPS, down 18.52% or $0.10 from last year’s $-0.54 per share. After $-0.65 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts -1.54% EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Suntrust Robinson given on Friday, January 29. The firm has “Neutral” rating by JP Morgan given on Friday, July 8. The firm has “Outperform” rating by FBR Capital given on Friday, July 8. Goldman Sachs initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Wednesday, November 18. Goldman Sachs has “Neutral” rating and $50 price target. The rating was upgraded by Standpoint Research on Tuesday, December 15 to “Buy”. Raymond James initiated the shares of JUNO in a report on Thursday, June 2 with “Outperform” rating. FBR Capital initiated the shares of JUNO in a report on Tuesday, August 18 with “Outperform” rating. The company was downgraded on Thursday, October 29 by Standpoint Research. The firm has “Outperform” rating given on Wednesday, July 22 by Northland Capital. The firm earned “Buy” rating on Friday, August 5 by Maxim Group.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.26, from 1.08 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Vanguard last reported 0.01% of its portfolio in the stock. D E Shaw Inc last reported 12,482 shares in the company. First Republic Inv Inc holds 0% or 5,935 shares in its portfolio. Moreover, Mycio Wealth Partners Limited Liability has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 500 shares. Savings Bank Of America De holds 39,016 shares or 0% of its portfolio. First Advsrs Lp owns 703,197 shares or 0.09% of their US portfolio. Aqr Capital Limited Liability Corporation has 0.02% invested in the company for 232,432 shares. Moreover, Geode Cap Mngmt Limited Liability Corporation has 0.01% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 497,300 shares. Us Retail Bank De has invested 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Shell Asset Mngmt has invested 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Moreover, Bessemer Gp has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 3,809 shares. Utah Retirement Sys holds 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 11,400 shares. Arrowpoint Asset Management Limited, a Colorado-based fund reported 526,717 shares. Boyer Corporon Wealth Ltd Llc accumulated 0.23% or 12,579 shares. First Allied Advisory has 21,152 shares for 0.05% of their US portfolio.
Another recent and important Juno Therapeutics Inc (NASDAQ:JUNO) news was published by Fool.com which published an article titled: “Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data” on September 21, 2016.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.